Since gain-of-function mutations in Proprotein convertase subtilisin-kexin type 9 (PCSK9) have been identified as contributors to familial hypercholesterolemia (3, 4), PCSK9 inhibitors have gained attention as novel lipid-lowering treatment. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.